Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Solid Tumors
Clinical trial register · United States · industry-sponsored

Solid Tumors Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9141 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Oct 2026, 03:16 UTC
9141
Studies in scope
industry-sponsored, all four open statuses
4966
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 33 Florida 25 Texas 22 New York 22 Michigan 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Incyte Corporation6 Zai Lab (Shanghai) Co., Ltd.2 Pfizer2 Daiichi Sankyo2 Adcentrx Therapeutics2
State
California33 Florida25 Texas22 New York22 Michigan17
All 40 states
Target enrolment
to

Solid Tumors trials in the USA

53 of 9141 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Recursion Pharmaceuticals Inc.
Phase 1/2
90
Michigan, Texas, Virginia
2026-09
Recruiting
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Arizona, California, Delaware, Florida, Kansas, Massachusetts, Minnesota, Nebraska
2026-05-06
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Connecticut, New York, South Carolina, Tennessee, Texas
2026-04-14
Recruiting
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
180
California, Connecticut, Florida, Missouri, New York, Virginia
2026-03-02
Recruiting
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Recruiting
Dewpoint Therapeutics
Phase 1
40
Texas, Virginia
2026-01
Recruiting
BeOne Medicines
Phase 1
63
Texas, Virginia
2025-11-10
Recruiting
A Study of DS3610a in Participants With Advanced Solid Tumor
NCT07159126Solid Tumors, Metastatic Solid Tumors
Daiichi Sankyo
Phase 1
70
Wisconsin
2025-10-09
Recruiting
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Recruiting
ABL Bio, Inc.
Phase 1/2
65
Ohio
2025-08-06
Recruiting
PumaRx Registry Trial
NCT06805461Solid Tumors
RenovoRx
Observational
1,000
Florida, Pennsylvania, Vermont
2025-08-01
Recruiting
DualityBio Inc.
Phase 2
450
California, Colorado, Florida, Georgia, Maryland, Nebraska, New York, Oregon
2025-07-18
Recruiting
Chugai Pharmaceutical
Phase 1
130
Michigan, Texas, Virginia
2025-06-05
Recruiting
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
NCT06736379Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC
DrugsKeytruda·Pembrolizumab
VLP Therapeutics
Phase 1
41
California
2025-05-13
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
285
Arizona, Florida, Minnesota, New York, Texas
2025-04-29
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Active, closed
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
DrugAmivantamab
ORIC Pharmaceuticals
Phase 1
76
New York, Virginia
2025-02-27
Recruiting
Hansoh BioMedical R&D Company
Phase 1
475
Florida, Indiana, North Carolina, Texas, Virginia
2025-02-26
By invitation
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
NCT06925685Hematologic Malignancies, Solid Tumors
Allogene Therapeutics
Observational
50
New York
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Recruiting
Adcentrx Therapeutics
Phase 1
68
California, Michigan, Minnesota, Texas, Utah, Virginia
2024-12-30
Recruiting
Daiichi Sankyo
Phase 1
150
Massachusetts, New York, Tennessee
2024-11-14
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Colorado, Florida, Missouri, Ohio, Tennessee, Texas
2024-07-24
Recruiting
GlaxoSmithKline
Phase 1
675
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2024-07-02
Recruiting
Quanta Therapeutics
Phase 1
250
California, Colorado, Connecticut, Florida, New York, North Carolina, Oklahoma, Tennessee
2024-02-05
Recruiting
Incyte Corporation
Phase 1
710
Arizona, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New York
2024-01-04
Active, closed
Gilead Sciences
Phase 1
45
Connecticut, Tennessee, Texas
2023-10-09
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah
2023-09-26
Recruiting
Incyte Corporation
Phase 1
570
California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas
2023-07-24
Recruiting
Boehringer Ingelheim
Phase 1
66
California, Connecticut, New Jersey
2023-02-24
Recruiting
Fore Biotherapeutics
Phase 2
254
California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, Missouri, Nebraska
2023-02-21
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Michigan, Missouri, Texas, Utah
2022-12-20
Recruiting
Arcus Biosciences, Inc.
Phase 1
362
Alabama, California, Florida, Georgia, Kentucky, Louisiana, Maryland, Massachusetts
2022-10-26
Recruiting
Pfizer
Phase 4
210
Arizona, Georgia, Massachusetts, Minnesota, Missouri, New Jersey, New York, North Carolina
2022-07-05
Active, closed
Incyte Corporation
Phase 1
291
California, Colorado, Connecticut, Florida, Georgia, New York, North Carolina, Pennsylvania
2022-07-05
Recruiting
Shionogi
Phase 1/2
282
California, Florida, Michigan, Pennsylvania, Texas
2022-05-30
Active, closed
Boehringer Ingelheim
Phase 1
42
Florida, New Jersey
2022-05-17
Active, closed
Pfizer
Phase 1/2
235
California, Massachusetts, Michigan, Missouri, Texas, Washington
2022-03-14
Recruiting
ORIC Pharmaceuticals
Phase 1/2
350
California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2022-03-10
Active, closed
Valent Technologies, LLC
Phase 1
20
Arizona, California, District of Columbia, Georgia, Indiana, Missouri, North Carolina, Ohio
2021-10-25
Recruiting
Spectrum Pharmaceuticals, Inc
Phase 2
40
New York, North Carolina, Ohio, Texas
2021-05-20
Active, closed
Hoffmann-La Roche
Phase 2
920
Arizona, California, Georgia, Idaho, Illinois, Indiana, Maryland, Michigan
2021-01-18
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Michigan
2019-03-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2018-08-21
Active, closed
Genentech, Inc.
Phase 1
123
Connecticut, Michigan, New York, Tennessee, Texas
2018-06-06
Recruiting
Apollomics Inc.
Phase 2
497
California, Florida, Massachusetts, North Carolina, Pennsylvania, Wisconsin
2017-09-27
Active, closed
ModernaTX, Inc.
Phase 1
161
California, District of Columbia, Florida, Massachusetts, New York, Ohio, Pennsylvania, Texas
2017-08-14
Active, closed
Hoffmann-La Roche
Phase 1/2
69
California, Colorado, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2016-05-03
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Alabama, Arizona, California, Connecticut, Georgia, Illinois, Maryland, Massachusetts
2015-07-14
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/solid-tumors

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,141 studies in total at the last sync on 19 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies listing the condition Solid Tumors.

How many Solid Tumors trials are recruiting in the US?

38 of the 53 studies on this page are recruiting new participants as of the 19 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Solid Tumors), 53 studies
PhaseStudiesRecruitingShare
Phase 1292154.7%
Phase 1/211720.8%
Phase 27613.2%
Phase 3325.7%
Observational213.8%
Phase 4111.9%

Most active sponsors

Lead sponsors with the most studies (Solid Tumors)
Lead sponsorStudiesRecruiting
Incyte Corporation64
Adcentrx Therapeutics21
Boehringer Ingelheim21
Daiichi Sankyo22
EMD Serono Research & Development Institute, Inc.20
Hoffmann-La Roche20
Jacobio Pharmaceuticals Co., Ltd.22
ORIC Pharmaceuticals22
Pfizer21
Zai Lab (Shanghai) Co., Ltd.22

Top states

Top states (Solid Tumors), by number of studies with a site there
StateStudies
California33
Florida25
New York22
Texas22
Michigan17
Massachusetts16
Connecticut12
Georgia12
Tennessee12
Maryland11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.